RHHBF Quote, Financials, Valuation and Earnings

CRISPR Therapeutics AG has a net margin of -- compared to Roche Holding AG's net margin of -11973.12%. Roche Holding AG's return on equity of 28.65% beat CRISPR Therapeutics AG's return on equity of -26.17%.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of -88.14%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 39.8%. Given that CRISPR Therapeutics AG has higher upside potential than Roche Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.303, which suggesting that the stock is 69.695% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.

Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.72%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 93.4% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Roche Holding AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Roche Holding AG's price-to-earnings ratio is 29.78x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.57x versus 132.71x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 28.26%. Roche Holding AG's return on equity of 28.65% beat Novartis AG's return on equity of 33.87%.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of -88.14%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could grow by 1.85%. Given that Novartis AG has higher upside potential than Roche Holding AG, analysts believe Novartis AG is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.303, which suggesting that the stock is 69.695% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.

Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.72%. Novartis AG offers a yield of 3.02% to investors and pays a quarterly dividend of $3.99 per share. Roche Holding AG pays 93.4% of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.9B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $3.9B. Notably, Roche Holding AG's price-to-earnings ratio is 29.78x while Novartis AG's PE ratio is 18.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.57x versus 4.79x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines Ltd. has a net margin of -- compared to Roche Holding AG's net margin of 8.84%. Roche Holding AG's return on equity of 28.65% beat BeOne Medicines Ltd.'s return on equity of 1.92%.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of -88.14%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $401.52 which suggests that it could grow by 21.16%. Given that BeOne Medicines Ltd. has higher upside potential than Roche Holding AG, analysts believe BeOne Medicines Ltd. is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.303, which suggesting that the stock is 69.695% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.

Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.72%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 93.4% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Roche Holding AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Roche Holding AG's price-to-earnings ratio is 29.78x while BeOne Medicines Ltd.'s PE ratio is 637.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.57x versus 7.40x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.